Multiple animal studies, few clinical case reports and one study have observed decreased testosterone production and gynaecomastia as adverse effect of imatinib therapy. We have prospectively studied testosterone, LH and FSH levels at baseline and at 6 months of imatinib treatment in 34 newly diagnosed male BCR-ABL positive CML patients. While none of the patients had gynaecomastia at 6 months, the proportion of patients with low testosterone level increased significantly from 11.8% at baseline to 58.8% (p < 0.001) and those with high LH and FSH increased significantly from 26.4% and 23.5% to 82.4% and 76.4%, respectively (p < 0.001 and p < 0.001). Serum testosterone levels decreased significantly (p = 0.002) and serum LH and FSH levels increased significantly at 6 months of imatinib therapy (p = 0.001 and p = 0.003) in comparison to baseline levels. The findings document the effect of imatinib on testosterone levels in adult CML patients much before than reported earlier.
LiesveldJLLichtmanMAChronic myelogenous leukemia and related disorders. In: KaushanksyKLichtmanMABeutlerEKippsTJSeligsohnUPrchalJT (eds). Williams hematology, 8th ed. New York: McGraw-Hill, 2010, pp. 1331–1379.
2.
SavonaMTalpazM. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer2008; 8: 341–350.
3.
BaccaraniMSaglioGGoldmanJ. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood2006; 108: 1809–1820.
4.
WetzlerMByrdJCBloomfieldCDAcute and chronic myeloid leukemia. In: KasperDLBraunwaldEFauciASHauserSLLongoDLJamesonJL (eds). Harrison’s principles of internal medicine, 18th ed. New York: McGraw Hill, 2005, pp. 631–641.
NurmioaMKallioJToppariaJ. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol2008; 25: 442–446.
7.
ApperleyJ. CML in pregnancy and childhood. Best Pract Res Clin Haematol2009; 22: 455–474.
8.
BascianiSde LucaGDolciS. Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes. Endocrinology2008; 149: 6226–6235.
9.
NurmioMToppariJZamanF. Inhibition of tyrosine kinases PDGFR and c-kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl2007; 30: 366–376.
10.
YaghmaeiPParivarKGhribiA. The biological effects of imatinib on male fertility of Wistar rats. IJFS2009; 3: 135–145.
11.
PrasadMRamnarayanKNaliniK. Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice. Indian J Pharmacol2011; 43: 389–392.
12.
KimHChangHMRyuMH. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. J Korean Med Sci2005; 20: 512–515.
13.
MarianiSBascianiSFabbriA. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril2011; 95: 15–17.
14.
MarianiSGionaFBascianiS. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet2008; 372: 111–112.
15.
Gambacorti-PasseriniCTornaghiLCavagniniF. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet2003; 361: 1954–1956.
16.
MackaySSmithRA. Effects of growth factors on testicular morphogenesis. Int Rev Cytol2007; 260: 113–173.
17.
KisselHTimokhinaIHardyMP. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signalling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J2000; 19: 1312–1326.
18.
BrennanJTilmannCCapelB. PDGFR-alpha mediates testis cord organization and fetal Leydig cell development in the XY gonad. Genes Dev2003; 17: 800–810.
19.
GnessiLBascianiSMarianiS. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice. J Cell Biol2000; 149: 1019–1026.
20.
HuangCTWeitsmanSRDykesBN. Stem cell factor and insulin-like growth factor-I stimulate luteinizing hormone-independent differentiation of rat ovarian theca cells. Biol Reprod2001; 64: 451–456.
21.
IamailAACawoodAMShortF. Testosterone assay: guideline for the provision of a clinical biochemistry service. Ann Clin Biochem1986; 23: 135–145.
22.
DikshitRPNagraniRYeoleB. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. Indian J Med Paediatr Oncol2011; 32: 96–100.
23.
ModakHKulkarniSKadakolGS. Prevalence and risk of leukemia in the multi-ethnic population of North Karnataka. Asian Pacific J Cancer Prev2011; 12: 671–675.
24.
CaocciGAtzeniSOrruN. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia2008; 22: 2127–2218.
25.
BallardiniPMarguttiGAlibertiC. Onset of male gynecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. Clin Drug Investig2009; 29: 487–490.
26.
TorinoFCorselloSMLongoR. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol2009; 6: 219–228.
27.
SetteCDolciSGeremiaR. The role of stem cell factor and of alternative c-kit gene products in the establishment, maintenance and function of germ cells. Int J Dev Biol2000; 44: 599–608.
28.
BhasinSCunninghamGRHayesSJ. Task Force, Endocrine Society. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2010; 95: 2536–2559.
